文献速递真菌感染

伊布替尼治疗期间脑曲霉病的临床特征与管理挑战

Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

CEREALS研究为全国性回顾性队列,纳入2006-2018年119例脑曲霉病患者,分析其中10例伊布替尼后发病者并与血液恶性肿瘤患者比较。伊布替尼相关脑曲霉病均为血行播散、血清半乳甘露聚糖阳性率低(33%)、6周死亡率40%(对照62%)。

要点

  • 伊布替尼相关脑曲霉病多在用药后中位2.9个月发生,均无抗霉菌预防。
  • 影像均为幕上脓肿无脑膜受累,常表现为局灶性神经功能缺损。
  • 血清半乳甘露聚糖敏感性有限(33%),需积极微生物学检查。

核心结论

  • 伊布替尼治疗期间脑曲霉病具有血行播散为主、血清半乳甘露聚糖阳性率低和死亡率较低的特点。

研究设计与样本

  • CEREALS研究为全国性回顾性队列,纳入2006-2018年119例脑曲霉病患者,其中10例为伊布替尼后发病。

主要发现

  • 10例中9例因慢性淋巴细胞白血病、1例因弥漫大B细胞淋巴瘤接受伊布替尼,中位既往治疗线数为2。
  • 脑曲霉病发生于伊布替尼起始后中位2.9个月,所有病例均为血行播散,70%有脑外受累(多为肺部)。
  • 所有患者脑影像显示幕上脓肿无脑膜受累,常表现为局灶性神经功能缺损。
  • 血清半乳甘露聚糖在受检患者中阳性率33%,仅见于中性粒细胞减少者。
  • 6周死亡率为40%,对比其他血液恶性肿瘤患者为62%。

临床怎么用

  • 对伊布替尼治疗患者出现局灶性神经症状应警惕脑曲霉病,即使血清半乳甘露聚糖阴性。
  • 需积极进行侵袭性微生物学检查以明确诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ibrutinib is a recognized risk factor for invasive fungal disease (IFD) recognized in the 2019 revised criteria of the European Organisation for Research and Treatment of Cancer. Cerebral aspergillosis (CA) under ibrutinib has been relatively frequently reported, but its particular characteristics remain insufficiently described. METHODS: The CEREALS study was a nationwide retrospective cohort of 119 patients diagnosed with CA between 2006 and 2018. We analysed 10 patients who developed CA following ibrutinib therapy and compared their clinical, radiological and outcome data with those of other patients with haematological malignancies from this cohort. RESULTS: Nine patients received ibrutinib for chronic lymphocytic leukaemia and one for diffuse large B-cell lymphoma after a median of two prior treatment lines. None received anti-mould prophylaxis, although 80% of them presented additional IFD risk factors. CA occurred a median of 2.9 months after ibrutinib initiation. All cases resulted from haematogenous dissemination, with extracerebral involvement in 70% of the patients, mostly the lungs. Brain imaging revealed supratentorial abscesses without meningeal involvement in all patients, typically manifesting with focal neurological deficits. Serum galactomannan was positive in 33% of tested patients, exclusively in neutropenic individuals. Six-week mortality was 40%. Compared with other haematological malignancy patients in the CEREALS cohort, ibrutinib-associated CA showed exclusive haematogenous spread, infrequent serum galactomannan positivity and lower mortality (40% versus 62%). CONCLUSIONS: Cerebral aspergillosis during ibrutinib therapy shows particular features. An invasive microbiological workup is often required, as serum galactomannan appears to have limited sensitivity in this context.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Serris A, Danion F, Benzakoun J, et al. Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges. J Antimicrob Chemother. 2026. PMID: 42549568. doi:10.1093/jac/dkag266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。